Skip to main content

Table 2 RVEDA/LVEDA ratio

From: Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism

Variable

DAA 6 μg/kg/h

DAA 12 μg/kg/h

DAA 18 μg/kg/h

DAA 24 μg/kg/h

Placebo

RVEDA/LVEDA Day 0

0.8 ± 0.3 (0.6 to 1.4)

1.0 0.3 (0.7 to 1.6)

1.0 0.4 (0.7 to 1.7)

0.9 ± 0.4 (0.6 to 1.6)

1.1 0.5 (0.6 to 2.8)

 

N = 6

N = 9

N = 9

N = 8

N = 15

RVEDA/LVEDA Day 6

0.7 ± 0.3 (0.5 to 1.2)

0.7 ± 0.2 (0.5 to 1.0)

0.8 ± 0.3 (0.5 to 1.5)

0.6 ± 0.2 (0.4 to 1.0)

0.7 ± 0.2 (0.5 to 1.1)

 

N = 5

N = 8

N = 8

N = 7

N = 15

RVEDA/LVEDA Day 90

0.5 ± 0.1 (0.4 to 0.7)

0.5 ± 0.1 (0.4 to 0.6)

0.6 ± 0.1 (0.4 to 0.6)

0.5 ± 0.1 (0.4 to 0.6)

0.6 ± 0.2 (0.3 to 0.9)

 

N = 5

N = 8

N = 8

N = 5

N = 11

  1. DAA, Drotrecogin alfa (activated); LVEDA, levt ventricular enddiastolic area; RVEDA, right ventricular enddiastolic area.